Innovent Biopharmaceutical Transformation
BD Strategy is Complementary to Innovent's Globalization Strategy
Strengthen Technical
Core-Competency
Strengthen Global Product Portfolio
Early/Mid Stage - GLOBAL RIGHTS
GLOBAL R&D PLATFORMS
In/out-license out opportunities,
accelerate US/EU presence
ADCS/ISAC
Antibody
discovery
platforms
"Next Generation Targets"
Cell
Therapies
Cytokine
Fusions
Prodrug
Technologies
Multi-specific
Abs/Proteins
New targeted therapies
Novel targets
■
mRNA
Technology
T/NK Cell
Validated new targets
ADC approaches
Intrabody
Engagers
Going From Domestic
to Global Market
Late Stage-CHINA RIGHTS
Collaborate on China molecules to synergize
with pipeline development and
commercialization
GLOBAL FOOTPRINT
Collaborate with experienced and
sophisticated partner
"Close to market focus"
Various validated targets
Oncology
■
Non-oncology (metabolic,
ophthalmology, immunology)
"Establish global brand"
■
Maximize the commercial
value of product portfolio
Accelerate to meet the global
unmet medical needs with
good image
As our BD transactions align with our strategy - we lay a strong path for globalization.
Innovent
Confidential
Copyright©2022 Innovent
21
24View entire presentation